- Todos > Public Health, Innovation, Intellectual Property and Trade > Intellectual Property (IP) and Trade
- Todos > Public Health, Innovation, Intellectual Property and Trade > Technology Transfer and Local Production
- Palabras clave > Intellectual Property Rights (IPR)
- Palabras clave > local pharmaceutical industry
- Palabras clave > local production
- Palabras clave > local production capacity
- Palabras clave > parallel importation
- Palabras clave > patentability criteria - policy options
- Palabras clave > pharmaceutical production
- Palabras clave > technology transfer
- Palabras clave > Trade Related Aspects of the Intellectual Property Rights (TRIPS)
- Palabras clave > TRIPS flexibilities
(2011; 204 pages)
Over the past few years, intellectual property rights (IPRs) have become a major economic, trade and investment issue, as illustrated by considerable increases in royalty payments and licensing fees in most areas of the world and the inclusion of intellectual property (IP) provisions in regional and bilateral trade and investment agreements. At the same time, concerns have been raised in many countries as to whether the IP system still serves its original purpose, i.e. the promotion of innovation and the transfer and dissemination of technology to the benefit of society, or whether exclusive rights are increasingly being used to defend selective private interests and prevent effective competition.
The present Guide has been prepared by the UNCTAD secretariat (Division on Investment and Enterprise (DIAE)) as part of its technical assistance activities in the area of IPRs and the promotion of pharmaceutical production and supply capacities in developing countries.
The objective of the present Guide is to provide concise and practical information on ways to promote local pharmaceutical production and improve access to medicines through a variety of policy tools, focusing on the flexibilities provided under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), and the interfaces between IP, investment, drugs regulation and procurement strategies. The Guide will be an important tool for training activities for stakeholders from selected developing countries, in an effort to build capacities for the creation of domestic legal frameworks conducive to the promotion of pharmaceutical production and supply capacities.